{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:24:16Z","timestamp":1793316256666,"version":"4.5.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diagn Pathol"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s13000-016-0506-2","type":"journal-article","created":{"date-parts":[[2016,6,27]],"date-time":"2016-06-27T10:18:24Z","timestamp":1467022704000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":99,"title":["Frequency of BRAF V600E mutations in 969 central nervous system neoplasms"],"prefix":"10.1186","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1083-1276","authenticated-orcid":false,"given":"Felix","family":"Behling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alonso","family":"Barrantes-Freer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Skardelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maike","family":"Nieser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"Christians","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Stockhammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veit","family":"Rohde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos","family":"Tatagiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Stadelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Schittenhelm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,6,27]]},"reference":[{"issue":"9916","key":"506_CR1","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/S0140-6736(13)62226-6","volume":"383","author":"D Hanahan","year":"2014","unstructured":"Hanahan D. Rethinking the war on cancer. Lancet. 2014;383(9916):558\u201363.","journal-title":"Lancet"},{"issue":"6","key":"506_CR2","doi-asserted-by":"crossref","first-page":"e293","DOI":"10.1016\/S1470-2045(14)71206-9","volume":"16","author":"PA Northcott","year":"2015","unstructured":"Northcott PA, Pfister SM, Jones DTW. Next-generation (epi)genetic drivers of childhood brain tumours and the outlook for targeted therapies. Lancet Oncol. 2015;16(6):e293\u2013302.","journal-title":"Lancet Oncol"},{"issue":"6","key":"506_CR3","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S0092-8674(04)00215-6","volume":"116","author":"PTC Wan","year":"2004","unstructured":"Wan PTC, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 2004;116(6):855\u201367.","journal-title":"Cell"},{"issue":"6892","key":"506_CR4","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","volume":"417","author":"H Davies","year":"2002","unstructured":"Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949\u201354.","journal-title":"Nature"},{"key":"506_CR5","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/978-3-319-22539-5_10","volume":"167","author":"DJ Wong","year":"2016","unstructured":"Wong DJ, Ribas A. Targeted Therapy for Melanoma. Caner Treat Res. 2016;167:251\u201362.","journal-title":"Caner Treat Res"},{"issue":"1","key":"506_CR6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00401-011-0841-z","volume":"122","author":"D Capper","year":"2011","unstructured":"Capper D, Preusser M, Habel A, Sahm F, Ackermann U, Schindler G, et al. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol. 2011;122(1):11\u20139.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"506_CR7","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jmoldx.2012.09.001","volume":"15","author":"E Colomba","year":"2013","unstructured":"Colomba E, Helias-Rodzewicz Z, von Deimling A, Marin C, Terrones N, Pechaud D, et al. Detection of BRAF p.V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing. J Mol Diagn. 2013;15(1):94\u2013100.","journal-title":"J Mol Diagn"},{"issue":"6","key":"506_CR8","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/PAT.0000000000000119","volume":"46","author":"K Dvorak","year":"2014","unstructured":"Dvorak K, Aggeler B, Palting J, McKelvie P, Ruszkiewicz A, Waring P, et al. Immunohitochemistry with the anti-BRAF V600E (VE1) antibody: impact of pre-analytical conditions and concordance with DNA sequencing in colorectal and papillary thyroid carcinoma. Pathology. 2014;46(6):509\u201317.","journal-title":"Pathology"},{"issue":"3","key":"506_CR9","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/annonc\/mds534","volume":"24","author":"M Ilie","year":"2013","unstructured":"Ilie M, Long E, Hofman V, Dadone B, Marquette CH, Mouroux J, et al. Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients. Ann Oncol. 2013;24(3):742\u20138.","journal-title":"Ann Oncol"},{"issue":"1","key":"506_CR10","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/2051-5960-1-20","volume":"1","author":"CM Ida","year":"2013","unstructured":"Ida CM, Vrana JA, Rodriguez FJ, Jentoft ME, Caron AA, Jenkins SM, et al. Immunohistochemistry is highly sensitive and specific for detection of BRAF V600E mutation in pleomorphic xanthoastrocytomas. Acta Neuropathol Commun. 2013;1(1):20.","journal-title":"Acta Neuropathol Commun"},{"issue":"5","key":"506_CR11","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1053\/j.semdp.2015.02.010","volume":"32","author":"LL Ritterhouse","year":"2015","unstructured":"Ritterhouse LL, Barletta JA. BRAF V600E mutation-specific antibody: A review. Semin Diagn Pathol. 2015;32(5):400\u20138.","journal-title":"Semin Diagn Pathol"},{"issue":"6","key":"506_CR12","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/nan.12246","volume":"41","author":"S Brandner","year":"2015","unstructured":"Brandner S, von Deimling A. Diagnostic, prognostic and predictive relevance of molecular markers in gliomas. Neuropahol Appl Neurobiol. 2015;41(6):694\u2013720.","journal-title":"Neuropahol Appl Neurobiol"},{"issue":"2","key":"506_CR13","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00401-011-0887-y","volume":"123","author":"D Capper","year":"2012","unstructured":"Capper D, Berghoff AS, Magerle M, Ilhan A, W\u00f6hrer A, Hackl M, et al. Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. Acta Neuropathol. 2012;123(2):223\u201333.","journal-title":"Acta Neuropathol"},{"issue":"16","key":"506_CR14","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1158\/1078-0432.CCR-13-0657","volume":"19","author":"S Cardarella","year":"2013","unstructured":"Cardarella S, Ogino A, Nishino M, Butaney M, Shen J, Lydon C, et al. Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer. Clin Cancer Res. 2013;19(16):4532\u201340.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"506_CR15","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/cam4.82","volume":"2","author":"C Villalva","year":"2013","unstructured":"Villalva C, Duranton-Tanneur V, Guilloteau K, Burel-Vandenbos F, Wager M, Doyen J, et al. EGFR, KRAS, BRAF, and HER-2 molecular status in brain metastases from 77 NSCLC patients. Cancer Med. 2013;2(3):296\u2013304.","journal-title":"Cancer Med"},{"issue":"Suppl 1","key":"506_CR16","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4137\/BIC.S25248","volume":"7","author":"D Barras","year":"2015","unstructured":"Barras D. BRAF Mutation in Colorectal Cancer: An Update. Biomarkers Cancer. 2015;7 Suppl 1:9\u201312.","journal-title":"Biomarkers Cancer"},{"issue":"7","key":"506_CR17","first-page":"1454","volume":"63","author":"ET Kimura","year":"2003","unstructured":"Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET\/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003;63(7):1454\u20137.","journal-title":"Cancer Res"},{"issue":"2","key":"506_CR18","first-page":"245","volume":"12","author":"M Xing","year":"2005","unstructured":"Xing M. BRAF mutation in thyroid cancer. Endocr RelatCancer. 2005;12(2):245\u201362.","journal-title":"Endocr RelatCancer"},{"issue":"12","key":"506_CR19","doi-asserted-by":"crossref","first-page":"4390","DOI":"10.1210\/jc.2012-1775","volume":"97","author":"R Elisei","year":"2012","unstructured":"Elisei R, Viola D, Torregrossa L, Giannini R, Romei C, Ugolini C, et al. The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study. J Clin Endocrinol Metab. 2012;97(12):4390\u20138.","journal-title":"J Clin Endocrinol Metab"},{"issue":"21","key":"506_CR20","doi-asserted-by":"crossref","first-page":"8673","DOI":"10.1158\/0008-5472.CAN-08-2097","volume":"68","author":"DTW Jones","year":"2008","unstructured":"Jones DTW, Kocialkowski S, Liu L, Pearson DM, B\u00e4cklund LM, Ichimura K, et al. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res. 2008;68(21):8673\u20137.","journal-title":"Cancer Res"},{"issue":"3","key":"506_CR21","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s00401-011-0802-6","volume":"121","author":"G Schindler","year":"2011","unstructured":"Schindler G, Capper D, Meyer J, Janzarik W, Omran H, Herold-Mende C, et al. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol. 2011;121(3):397\u2013405.","journal-title":"Acta Neuropathol"},{"issue":"12","key":"506_CR22","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/j.ejso.2015.09.012","volume":"41","author":"E Tabouret","year":"2015","unstructured":"Tabouret E, Bequet C, Denicola\u00ef E, Barri\u00e9 M, Nanni I, Metellus P, et al. BRAF mutation and anaplasia may be predictive factors of progression-free survival in adult pleomorphic xanthoastrocytoma. Eur J Surg Oncol. 2015;41(12):1685\u201390.","journal-title":"Eur J Surg Oncol"},{"issue":"6","key":"506_CR23","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s00401-013-1120-y","volume":"125","author":"S Dahiya","year":"2013","unstructured":"Dahiya S, Haydon DH, Alvarado D, Gurnett CA, Gutmann DH, Leonard JR. BRAF(V600E) mutation is a negative prognosticator in pediatric ganglioglioma. Acta Neuropathol. 2013;125(6):901\u201310.","journal-title":"Acta Neuropathol"},{"issue":"4","key":"506_CR24","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s00401-015-1467-3","volume":"130","author":"CY Ho","year":"2015","unstructured":"Ho CY, Mobley BC, Gordish-Dressman H, VandenBussche CJ, Mason GE, Bornhorst M, et al. A clinicopathologic study of diencephalic pediatric low-grade gliomas with BRAF V600 mutation. Acta Neuropathol. 2015;130(4):575\u201385.","journal-title":"Acta Neuropathol"},{"issue":"6","key":"506_CR25","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/ng.2611","volume":"45","author":"J Zhang","year":"2013","unstructured":"Zhang J, Wu G, Miller CP, Tatevossian RG, Dalton JD, Tang B, et al. Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat Genet. 2013;45(6):602\u201312.","journal-title":"Nat Genet"},{"issue":"4","key":"506_CR26","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.cancergen.2014.03.002","volume":"207","author":"JJ Roth","year":"2014","unstructured":"Roth JJ, Santi M, Rorke-Adams LB, Harding BN, Busse TM, Tooke LS, et al. Diagnostic application of high resolution single nucleotide polymorphism array analysis for children with brain tumors. Cancer Genet. 2014;207(4):111\u201323.","journal-title":"Cancer Genet"},{"issue":"20","key":"506_CR27","doi-asserted-by":"crossref","first-page":"8188","DOI":"10.1073\/pnas.1300252110","volume":"110","author":"LA Ramkissoon","year":"2013","unstructured":"Ramkissoon LA, Horowitz PM, Craig JM, Ramkissoon SH, Rich BE, Schumacher SE, et al. Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1. Proc Natl Acad Sci U S A. 2013;110(20):8188\u201393.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"506_CR28","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s11060-014-1398-1","volume":"117","author":"GR Cruz","year":"2014","unstructured":"Cruz GR, Dias Oliveira I, Moraes L, Del Giudice PM, de Seixas Alves MT, Capellano AM, et al. Analysis of KIAA1549-BRAF fusion gene expression and IDH1\/IDH2 mutations in low grade pediatric astrocytomas. J Neuro-Oncol. 2014;117(2):235\u201342.","journal-title":"J Neuro-Oncol"},{"issue":"1","key":"506_CR29","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00432-015-2006-2","volume":"142","author":"M Gierke","year":"2016","unstructured":"Gierke M, Sperveslage J, Schwab D, Beschorner R, Ebinger M, Schuhmann MU, et al. Analysis of IDH1-R132 mutation, BRAF V600 mutation and KIAA1549-BRAF fusion transcript status in central nervous system tumors supports pediatric tumor classification. J Cancer Res Clin Oncol. 2016;142(1):89\u2013100.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"10","key":"506_CR30","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1200\/JCO.2012.44.1568","volume":"31","author":"S Rush","year":"2013","unstructured":"Rush S, Foreman N, Liu A. Brainstem ganglioglioma successfully treated with vemurafenib. J Clin Oncol. 2013;31(10):e159\u201360.","journal-title":"J Clin Oncol"},{"issue":"6","key":"506_CR31","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/pbc.24891","volume":"61","author":"F Bautista","year":"2014","unstructured":"Bautista F, Paci A, Minard-Colin V, Dufour C, Grill J, Lacroix L, et al. Vemurafenib in pediatric patients with BRAFV600E mutated high-grade gliomas. Pediatr Blood Cancer. 2014;61(6):1101\u20133.","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"506_CR32","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s11060-013-1176-5","volume":"114","author":"MC Chamberlain","year":"2013","unstructured":"Chamberlain MC. Salvage therapy with BRAF inhibitors for recurrent pleomorphic xanthoastrocytoma: a retrospective case series. J Neuro-Oncol. 2013;114(2):237\u201340.","journal-title":"J Neuro-Oncol"},{"issue":"10","key":"506_CR33","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1097\/NEN.0000000000000240","volume":"74","author":"A Usubalieva","year":"2015","unstructured":"Usubalieva A, Pierson CR, Kavran CA, Huntoon K, Kryvenko ON, Mayer TG, et al. Primary Meningeal Pleomorphic Xanthoastrocytoma With Anaplastic Features: A Report of 2 Cases, One With BRAFV600E Mutation and Clinical Response to the BRAF Inhibitor Dabrafenib. J Neuropathol Exp Neurol. 2015;74(10):960\u20139.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"11","key":"506_CR34","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1002\/pbc.25084","volume":"61","author":"M Skrypek","year":"2014","unstructured":"Skrypek M, Foreman N, Guillaume D, Moertel C. Pilomyxoid astrocytoma treated successfully with vemurafenib. Pediatr Blood Cancer. 2014;61(11):2099\u2013100.","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"506_CR35","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1097\/PAS.0b013e31827f9c5e","volume":"37","author":"BK Kleinschmidt-DeMasters","year":"2013","unstructured":"Kleinschmidt-DeMasters BK, Aisner DL, Birks DK, Foreman NK. Epithelioid GBMs show a high percentage of BRAF V600E mutation. Am J Surg Pathol. 2013;37(5):685\u201398.","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"506_CR36","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1186\/1471-2407-14-258","volume":"14","author":"GW Robinson","year":"2014","unstructured":"Robinson GW, Orr BA, Gajjar A. Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy. BMC Cancer. 2014;14(1):258.","journal-title":"BMC Cancer"},{"issue":"4","key":"506_CR37","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1097\/PAS.0000000000000363","volume":"39","author":"BK Kleinschmidt-DeMasters","year":"2015","unstructured":"Kleinschmidt-DeMasters BK, Aisner DL, Foreman NK. BRAF VE1 immunoreactivity patterns in epithelioid glioblastomas positive for BRAF V600E mutation. Am J Surg Pathol. 2015;39(4):528\u201340.","journal-title":"Am J Surg Pathol"},{"key":"506_CR38","doi-asserted-by":"crossref","unstructured":"Nicolaides TP, Li H, Solomon DA, Hariono S, Hashizume R, Barkovich K, et al. Targeted therapy for BRAFV600E malignant astrocytoma. Clin. Cancer Res. 2011;17(24):7597\u2013604","DOI":"10.1158\/1078-0432.CCR-11-1456"},{"issue":"2","key":"506_CR39","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00401-004-0936-x","volume":"109","author":"D Basto","year":"2005","unstructured":"Basto D, Trovisco V, Lopes JM, Martins A, Pardal F, Soares P, et al. Mutation analysis of B-RAF gene in human gliomas. Acta Neuropathol. 2005;109(2):207\u201310.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"506_CR40","first-page":"17","volume":"23","author":"C Hagemann","year":"2009","unstructured":"Hagemann C, Gloger J, Anacker J, Said HM, Gerngras S, K\u00fchnel S, et al. RAF expression in human astrocytic tumors. Int J Mol Med. 2009;23(1):17\u201331.","journal-title":"Int J Mol Med"},{"issue":"6","key":"506_CR41","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s00401-004-0929-9","volume":"108","author":"CB Knobbe","year":"2004","unstructured":"Knobbe CB, Reifenberger J, Reifenberger G. Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas. Acta Neuropathol. 2004;108(6):467\u201370.","journal-title":"Acta Neuropathol"},{"issue":"2","key":"506_CR42","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/BF02479430","volume":"18","author":"A Saito","year":"2001","unstructured":"Saito A, Nakazato Y, Yoshii Y, Hyodo A, Harakuni T, Toita T, et al. Anaplastic meningioma with papillary, rhabdoid, and epithelial features: a case report. Brain Tumor Pathol. 2001;18(2):155\u20139.","journal-title":"Brain Tumor Pathol"},{"key":"506_CR43","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ijscr.2014.10.048","volume":"6C","author":"R Parameshwaran Nair","year":"2015","unstructured":"Parameshwaran Nair R, Vinod Sarma Y, Nayal B, Kaur Dil S, Tripathi PK. Metastatic rhabdoid meningioma of the parotid - Mimicking primary salivary gland neoplasm. Int J Surg Case Rep. 2015;6C:104\u20136.","journal-title":"Int J Surg Case Rep"},{"issue":"3","key":"506_CR44","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3109\/08880018.2014.936058","volume":"32","author":"O Mordechai","year":"2015","unstructured":"Mordechai O, Postovsky S, Vlodavsky E, Eran A, Constantini S, Dotan E, et al. Metastatic rhabdoid meningioma with BRAF V600E mutation and good response to personalized therapy: case report and review of the literature. Pediatr Hematol Oncol. 2015;32(3):207\u201311.","journal-title":"Pediatr Hematol Oncol"},{"issue":"6","key":"506_CR45","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s00401-013-1118-5","volume":"125","author":"J Sperveslage","year":"2013","unstructured":"Sperveslage J, Gierke M, Capper D, Honegger J, Sipos B, Beschorner R, et al. VE1 immunohistochemistry in pituitary adenomas is not associated with BRAF V600E mutation. Acta Neuropathol. 2013;125(6):911\u20132.","journal-title":"Acta Neuropathol"},{"issue":"3","key":"506_CR46","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1200\/JCO.2009.23.3452","volume":"28","author":"AD Roth","year":"2010","unstructured":"Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(3):466\u201374.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"39","key":"506_CR47","doi-asserted-by":"crossref","first-page":"41453","DOI":"10.18632\/oncotarget.6162","volume":"6","author":"C Schafroth","year":"2015","unstructured":"Schafroth C, Galv\u00e1n JA, Centeno I, Koelzer VH, Dawson HE, Sokol L, et al. VE1 immunohistochemistry predicts BRAF V600E mutation status and clinical outcome in colorectal cancer. Oncotarget. 2015;6(39):41453\u201363.","journal-title":"Oncotarget"},{"issue":"1","key":"506_CR48","doi-asserted-by":"crossref","first-page":"e259","DOI":"10.1038\/cddis.2011.136","volume":"3","author":"M Colombino","year":"2012","unstructured":"Colombino M, Sperlongano P, Izzo F, Tatangelo F, Botti G, Lombardi A, et al. BRAF and PIK3CA genes are somatically mutated in hepatocellular carcinoma among patients from South Italy. Cell Death Dis. 2012;3(1):e259.","journal-title":"Cell Death Dis"},{"issue":"4","key":"506_CR49","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378\u201390.","journal-title":"N Engl J Med"},{"issue":"1","key":"506_CR50","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1158\/1535-7163.MCT-13-0561","volume":"13","author":"H Vin","year":"2014","unstructured":"Vin H, Ching G, Ojeda SS, Adelmann CH, Chitsazzadeh V, Dwyer DW, et al. Sorafenib suppresses JNK-dependent apoptosis through inhibition of ZAK. Mol Cancer Ther. 2014;13(1):221\u20139.","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"506_CR51","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/PAI.0b013e31827ce693","volume":"21","author":"M Preusser","year":"2013","unstructured":"Preusser M, Berghoff AS, Capper D, von Deimling A, Maroske F, Brodowicz T, et al. No evidence for BRAF-V600E mutations in gastroeosophageal tumors: results from a high-throughput analysis of 534 cases using a mutation-specific antibody. Appl Immunohistochem Mol Morphol. 2013;21(5):426\u201330.","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"3","key":"506_CR52","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1365-2265.2006.02735.x","volume":"66","author":"I Ewing","year":"2007","unstructured":"Ewing I, Pedder-Smith S, Franchi G, Ruscica M, Emery M, Vax V, et al. A mutation and expression analysis of the oncogene BRAF in pituitary adenomas. Clin Endocrinol. 2007;66(3):348\u201352.","journal-title":"Clin Endocrinol"},{"issue":"6","key":"506_CR53","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1309\/AJCP37TLZLTUAOJL","volume":"141","author":"DA Mordes","year":"2014","unstructured":"Mordes DA, Lynch K, Campbell S, Dias-Santagata D, Nose V, Louis DN, et al. VE1 antibody immunoreactivity in normal anterior pituitary and adrenal cortex without detectable BRAF V600E mutations. Am J Clin Pathol. 2014;141(6):811\u20135.","journal-title":"Am J Clin Pathol"},{"issue":"3","key":"506_CR54","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.humpath.2013.10.026","volume":"45","author":"SF Kuan","year":"2014","unstructured":"Kuan SF, Navina S, Cressman KL, Pai RK. Immunohistochemical detection of BRAF V600E mutant protein using the VE1 antibody in colorectal carcinoma is highly concordant with molecular testing but requires rigorous antibody optimization. Hum Pathol. 2014;45(3):464\u201372.","journal-title":"Hum Pathol"},{"issue":"12","key":"506_CR55","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.1158\/1535-7163.MCT-15-0615","volume":"14","author":"JS Estrella","year":"2015","unstructured":"Estrella JS, Tetzlaff M, Bassett RL, Patel KP, Williams MD, Curry J, et al. Assessment of BRAF V600E Status in Colorectal Carcinoma: Tissue-Specific Discordances between Immunohistochemistry and Sequencing. Mol Cancer Ther. 2015;14(12):2887\u201395.","journal-title":"Mol Cancer Ther"}],"container-title":["Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-016-0506-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,10]],"date-time":"2019-09-10T03:50:53Z","timestamp":1568087453000},"score":1,"resource":{"primary":{"URL":"http:\/\/diagnosticpathology.biomedcentral.com\/articles\/10.1186\/s13000-016-0506-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,27]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["506"],"URL":"https:\/\/doi.org\/10.1186\/s13000-016-0506-2","relation":{},"ISSN":["1746-1596"],"issn-type":[{"value":"1746-1596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,27]]},"article-number":"55"}}